Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
5
IVVD Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
-39.85%
Day range:
$0.73 - $0.80
52-week range:
$0.35 - $4.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.34x
Volume:
2.8M
Avg. volume:
6.5M
1-year change:
-75.58%
Market cap:
$90.3M
Revenue:
$25.4M
EPS (TTM):
-$1.44
Analysts' Opinion
-
Consensus RatingInvivyd has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.60, Invivyd has an estimated upside of 774.64% from its current price of $0.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.80 representing -6.02% downside risk from its current price of $0.75.
Fair Value
-
According to the consensus of 2 analysts, Invivyd has 774.64% upside to fair value with a price target of $6.60 per share.
IVVD vs. S&P 500
-
Over the past 5 trading days, Invivyd has underperformed the S&P 500 by -6.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Invivyd does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Invivyd has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Invivyd reported revenues of $13.8M.
Earnings Growth
-
Invivyd has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Invivyd reported earnings per share of -$0.15.
Enterprise value:
20.9M
EV / Invested capital:
0.31x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-139.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $13.8M | |
| Gross Profit | -- | -- | -- | -- | $13.1M | |
| Operating Income | -$226.3M | -$207.8M | -$176.9M | -$77.4M | -$19.2M | |
| EBITDA | -$225.8M | -$205.8M | -$173.8M | -$76.8M | -$17.7M | |
| Diluted EPS | -$2.23 | -$1.81 | -$1.44 | -$0.67 | -$0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $616.7M | $376.9M | $224.9M | $100.7M | |
| Total Assets | -- | $620.1M | $383.2M | $229.2M | $129.5M | |
| Current Liabilities | -- | $62.1M | $25M | $50.3M | $62M | |
| Total Liabilities | -- | $62.1M | $27.2M | $51.7M | $62M | |
| Total Equity | -- | $558M | $356M | $177.5M | $67.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$220M | -$173.2M | -$170.5M | -$59.2M | -$37.6M | |
| Cash From Investing | -$230.7M | $280.7M | -$140K | $77.9M | $5K | |
| Cash From Financing | $506K | $1M | $39.3M | $141K | $77K | |
| Free Cash Flow | -$220M | -$173.8M | -$170.6M | -$59.2M | -$37.6M | |
IVVD
Sector
Market Cap
$90.3M
$39.2M
Price % of 52-Week High
15.92%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-75.58%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.78
200-day SMA
Sell
Level
$0.98
Bollinger Bands (100)
Sell
Level
0.42 - 1.22
Chaikin Money Flow
Buy
Level
194.2M
20-day SMA
Sell
Level
$1.00
Relative Strength Index (RSI14)
Sell
Level
41.07
ADX Line
Buy
Level
17.83
Williams %R
Buy
Level
-90.5163
50-day SMA
Sell
Level
$0.95
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
732.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-13.1892)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Stock Forecast FAQ
In the current month, IVVD has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IVVD average analyst price target in the past 3 months is $6.60.
-
Where Will Invivyd Stock Be In 1 Year?
According to analysts, the consensus estimate is that Invivyd share price will rise to $6.60 per share over the next 12 months.
-
What Do Analysts Say About Invivyd?
Analysts are divided on their view about Invivyd share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Invivyd is a Sell and believe this share price will drop from its current level to $0.80.
-
What Is Invivyd's Price Target?
The price target for Invivyd over the next 1-year time period is forecast to be $6.60 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IVVD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Invivyd is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of IVVD?
You can purchase shares of Invivyd via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Invivyd shares.
-
What Is The Invivyd Share Price Today?
Invivyd was last trading at $0.75 per share. This represents the most recent stock quote for Invivyd. Yesterday, Invivyd closed at $0.75 per share.
-
How To Buy Invivyd Stock Online?
In order to purchase Invivyd stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
